Daclizumab has a definite role in preventing acute rejection in renal transplants and may be beneficial in other solid organ transplants
New Drugs and Profile Reports
- 12 Downloads
KeywordsAcute Rejection Renal Transplant Recipient Graft Versus Host Disease Immunosuppressive Regimen Liver Transplant Recipient
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Unable to display preview. Download preview PDF.
- 8.Chang GJ, Mahanty HD, Vincenti F, et al. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transpl 2000; 14 (6): 550–4CrossRefGoogle Scholar
- 12.Kato T, Neff G, Montalbano M, et al. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C — a preliminary report of a prospective randomized trial. Am J Transplant 2001; 1 Suppl. 1: 179Google Scholar
- 14.Heffron TG, Smallwood GA, de Vera M, et al. Hepatitis C recurrence following daclizumab induction in liver transplantation [abstract]. Hepatology 2000 Oct; 32 (Pt2): 346Google Scholar
- 19.Willenbacher W, Basara N, Kirsten D, et al. Treatment of severe steroid-resistant GVHD with a monoclonal interleukin-2 receptor agonist (daclizumab [DC]) [abstract]. Bone Marrow Transplant 2000 Mar; 25 Suppl. 1: S156Google Scholar
© Adis International Limited 2002